20th Annual New York Lung Cancers Symposium®

Release Date: December 5, 2025

Expiration Date: December 5, 2026

Activity Overview

The New York Lung Cancers Symposium^® is a comprehensive overview of multidisciplinary lung cancer treatment. Now in its twentieth year, this meeting is designed to increase your knowledge of lung cancer therapy, including the roles that surgery, radiology, pulmonology, and pathology play, to ensure the most accurate diagnosis of lung cancers. Thought leaders from the New York area discuss optimal approaches for early-stage and locally advanced disease and present the latest data on immunotherapy and targeted agents in metastatic lung cancers. These multidisciplinary interactions are illustrated in a tumor board format, in which participants at the meeting presented questions and clinical challenges from their practices.

This educational activity is an archive of the live presentation held on November 15, 2025.

For more information about this educational activity, including details about the faculty and their disclosures, please click here.

Partner Acknowledgment

PER^® is proud to partner with the Empire State Hematology & Oncology Society, the International Association for the Study of Lung Cancer (IASLC), LUNGEVITY, and Memorial Sloan Kettering Cancer Center.

Target Audience

This educational activity is directed toward medical oncologists, along with surgeons, radiologists, general scientists, young investigators, advanced practice providers, nurses, and pharmacists who manage patients with lung cancers. Other health care professionals interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, learners will be better able to:

• Evaluate emerging therapeutic targets and new biomarker testing strategies to guide precision medicine approaches for patients with lung cancers
• Assess recent efficacy and safety data from pivotal clinical trials investigating novel therapies and combination approaches for the treatment of localized and metastatic lung cancers
• Apply the latest data, guideline recommendations, and disease/patient-specific factors to optimize precision treatment approaches for patients with localized and metastatic lung cancers
• Develop evidence-based strategies to mitigate treatment-related adverse effects associated with novel therapies and combination approaches for the treatment of lung cancers

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC (PER^®) have no relevant financial relationships with ineligible companies.

PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.